Early Heart Procedures Don't Extend Survival
A 13-year follow-up of ISCHEMIA-EXTEND finds invasive treatment for stable coronary disease does not improve long-term survival.
Updated on Nov. 9, 2026 in Heart Disease
Live Poll
If you had stable heart disease, would you want early procedures even without a survival benefit?
The ISCHEMIA-EXTEND study found that patients with stable coronary artery disease who received early invasive procedures had a 26 percent chance of death, compared with 27 percent for those treated conservatively with medications and lifestyle changes. The results were presented November 7 at the American Heart Association's Scientific Sessions and published in the Journal of the American Medical Association.
Why it matters
Cardiologists have often recommended early procedures on the assumption that acting early might prevent later life-threatening problems, so these findings challenge that long-standing approach for stable patients. The results suggest that routine invasive treatment may not offer a survival benefit over medical therapy in this population.
The trial followed patients for up to 13 years and confirmed survival status for 96 percent of participants, with the 26 percent and 27 percent death rates coming from an analysis of the full follow-up period. Nonfatal heart attacks, repeat procedures and quality of life after the initial trial period were not tracked, leaving those outcomes unmeasured.
The players
NYU Langone Health
NYU Langone Health is a major academic medical center in New York City that led the research team and issued the public announcement of the study results.
American Heart Association
The American Heart Association is a leading nonprofit organization focused on cardiovascular health whose Scientific Sessions hosted the presentation of the study.
Journal of the American Medical Association
The Journal of the American Medical Association is one of the most widely read general medical journals in the world and published the peer-reviewed study.
The details
The ISCHEMIA-EXTEND study extended the original ISCHEMIA trial's follow-up for patients with stable coronary artery disease. Participants were assigned either to routine stent implants or bypass surgery combined with medications and behavioral changes, or to medications and lifestyle changes alone, with procedures reserved for cases where medical therapy failed.
Timeline
Up to 13 years of follow-up recorded the 1,071 deaths in the study.
November 7, 2026: Results were presented at the American Heart Association's Scientific Sessions.
November 8, 2026: NYU Langone Health published its press release on the findings.
Health Landscape
The ISCHEMIA-EXTEND results extend the original ISCHEMIA trial, which compared invasive and conservative strategies in stable coronary disease, across a much longer follow-up window. Together, the two studies add long-term evidence to a debate over whether routine procedures should be the default for patients whose chest pain is controlled by medication.
For people with stable coronary artery disease, the findings suggest that starting with medications and lifestyle changes may carry no survival disadvantage compared with early stents or bypass surgery. Patients should still discuss symptom relief and quality of life with their cardiologist, since the study did not measure those outcomes after the initial trial period.
The takeaway
For patients with stable heart disease, medication and lifestyle changes can be a credible first approach with survival comparable to early procedures. Decisions about treatment should still weigh symptom relief and quality of life alongside the survival evidence.
Further reading
Explore more on Heart Disease to see how treatment strategies are evaluated over time.
More information
Read the full ISCHEMIA-EXTEND study in the Journal of the American Medical Association.
Source note: This article includes information reported by News-Medical.
Live Poll
If you had stable heart disease, would you want early procedures even without a survival benefit?
